The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.
BEDMINSTER, N.J., and DUBLIN, Ireland, March 29, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN ), a pharmaceutical company focused on improving cardiovascular health, today announced that its licensee in Canada, HLS Therapeutics Inc. (TSX: HLS ), has received formal confirmation
BEDMINSTER, N.J. , and DUBLIN, Ireland , March 28, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that, as planned, it submitted a supplemental new drug application (sNDA) to the U.S.
BEDMINSTER, N.J. , and DUBLIN, Ireland , March 28, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today confirmed that the American Diabetes Association® (ADA) issued important updates to the Standards of Medical
Anti-Oxidant Effects of Eicosapentaenoic Acid Data at Pharmacologic Concentrations Also Presented BEDMINSTER, N.J. , and DUBLIN, Ireland , March 19, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, in addition to its
BEDMINSTER, N.J. and DUBLIN, Ireland , March 18, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, announced today that real-world data reported by the U.S. Veteran’s Administration supports that patients with
Approximately 159 Fewer Major Adverse Cardiovascular Events per 1000 Patients Studied Data Show Relative Benefits of Vascepa Usage Grow Over Time Amarin Schedules Webcast Discussion of Presented Data Today, March 18, 2019 at 4:00-5:00 pm CT BEDMINSTER, N.J.
BEDMINSTER, N.J. and DUBLIN, Ireland , March 16, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, announced today the presentation of data and analysis which concluded that over nine million atherosclerotic
BEDMINSTER, N.J. , and DUBLIN, Ireland , March 05, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
Multiple Scientific Presentations Scheduled for American College of Cardiology’s 68th Annual Scientific Session Amarin to Webcast Discussion of Presented Data March 18 , 4:00-5:00 pm Central Time BEDMINSTER, N.J. , and DUBLIN, Ireland , March 04, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc
Record Revenue of $229.2 Million and $ 77.3 Million for Full Year and Fourth Quarter 2018 REDUCE-IT™ sNDA Submission Remains on Schedule to be Filed Before the End of Q1 2019 Management to Host Conference Call at 7:30 a.m. ET Today BEDMINSTER, N.J. , and DUBLIN, Ireland , Feb.